Vera Therapeutics (NASDAQ:VERA) Announces Earnings Results

Vera Therapeutics (NASDAQ:VERA) posted its earnings results on Thursday. The company reported ($1.30) EPS for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.32, FiscalAI reports. The firm had revenue of $10.28 million during the quarter, compared to analysts’ expectations of $3.42 million.

Here are the key takeaways from Vera Therapeutics’ conference call:

• TRUTAKNA showed strong kidney-function results in ORIGIN 3: At 104 weeks, it reduced the risk of kidney disease progression by 76% versus placebo, with kidney-function decline near a physiologic rate. Vera submitted an FDA application seeking full approval and plans an EU application in the first quarter of 2027.
• The early U.S. launch generated about 700 Patient Start Forms since the July approval, and third-quarter product revenue was $10.3 million; management said roughly half the revenue reflected demand and half inventory. The company said prescriptions span patients with both higher and lower proteinuria, while acknowledging that adoption is still at an early stage.
• Interim PIONEER results showed a 52% reduction in proteinuria from baseline at week 24 among 101 adults across broader IgA nephropathy cohorts, including patients with lower kidney function. Results in primary membranous nephropathy were preliminary, based on 16 patients.
• Spending and cash use increased as Vera funded commercialization: third-quarter net loss was $93.7 million, and operating cash use totaled $305.9 million for the first nine months of 2026. The company reported $384 million in cash and marketable securities at quarter-end and borrowed $75 million in October; additional debt capacity is subject to conditions.

Vera Therapeutics Stock Performance

Shares of VERA opened at $29.78 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The stock has a market capitalization of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. The business’s fifty day moving average price is $31.60 and its 200 day moving average price is $36.68. Vera Therapeutics has a 12-month low of $23.86 and a 12-month high of $56.05.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the sale, the chief executive officer owned 235,244 shares in the company, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VERA. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. Raymond James Financial set a $87.00 price objective on Vera Therapeutics in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Guggenheim reduced their price objective on shares of Vera Therapeutics from $76.00 to $66.00 and set a “buy” rating for the company in a research report on Friday. Finally, Leerink Partners started coverage on Vera Therapeutics in a research report on Monday, October 12th. They issued a “market perform” rating and a $34.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $74.93.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.